cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Company profile
Ticker
CPIX
Exchange
Website
CEO
A. J. Kazimi
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
CPIX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Mar 24
8-K
Other Events
20 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
5 Mar 24
EFFECT
Notice of effectiveness
27 Dec 23
CORRESP
Correspondence with SEC
21 Dec 23
UPLOAD
Letter from SEC
19 Dec 23
Transcripts
CPIX
Earnings call transcript
2023 Q3
7 Nov 23
CPIX
Earnings call transcript
2023 Q2
8 Aug 23
CPIX
Earnings call transcript
2023 Q1
9 May 23
CPIX
Earnings call transcript
2022 Q4
7 Mar 23
CPIX
Earnings call transcript
2022 Q3
13 Nov 22
CPIX
Earnings call transcript
2022 Q2
13 Aug 22
CPIX
Earnings call transcript
2022 Q1
14 May 22
CPIX
Earnings call transcript
2021 Q4
9 Mar 22
CPIX
Earnings call transcript
2021 Q3
13 Nov 21
CPIX
Earnings call transcript
2021 Q3
9 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.51 mm | 18.51 mm | 18.51 mm | 18.51 mm | 18.51 mm | 18.51 mm |
Cash burn (monthly) | (no burn) | 86.13 k | 622.20 k | 411.73 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | 589.88 k | 4.26 mm | 2.82 mm | n/a | n/a |
Cash remaining | n/a | 17.92 mm | 14.25 mm | 15.69 mm | n/a | n/a |
Runway (months of cash) | n/a | 208.0 | 22.9 | 38.1 | n/a | n/a |
Institutional ownership, Q2 2023
16.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 2.43 bn |
Total shares | 2.40 mm |
Total puts | 2.10 k |
Total calls | 32.30 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 560.74 k | $824.00 k |
Dimensional Fund Advisors | 507.29 k | $745.72 mm |
Vanguard | 374.83 k | $550.99 mm |
Bridgeway Capital Management | 286.66 k | $421.38 mm |
Acadian Asset Management | 188.16 k | $275.00 k |
BLK Blackrock | 113.69 k | $167.13 mm |
National Asset Management | 90.30 k | $132.74 mm |
Geode Capital Management | 74.58 k | $109.64 mm |
STT State Street | 43.05 k | $63.28 mm |
Two Sigma Investments | 33.23 k | $48.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Martin S Brown JR | Common Stock | Grant | Acquire A | No | No | 1.71 | 1,000 | 1.71 k | 6,000 |
25 Mar 24 | Young Caroline | Common Stock | Grant | Acquire A | No | No | 1.71 | 1,000 | 1.71 k | 26,701 |
25 Mar 24 | Joseph C Galante | Common Stock | Grant | Acquire A | No | No | 1.71 | 1,000 | 1.71 k | 59,356 |
25 Mar 24 | Jones James | Common Stock | Grant | Acquire A | No | No | 1.71 | 1,000 | 1.71 k | 33,407 |
25 Mar 24 | Krogulski Kenneth | Common Stock | Grant | Acquire A | No | No | 1.71 | 5,000 | 8.55 k | 241,277 |